

संख्या / F. No. 19(697)/2016/Div. II/NPPA

भारत सरकार

Government of India

रसायन और उर्वरक मंत्रालय

Ministry of Chemicals & Fertilizers

औषध विभाग

Department of Pharmaceuticals

राष्ट्रीय औषध मूल्य निर्धारण प्राधिकरण

National Pharmaceutical Pricing Authority

तीसरी/पांचवी मंजिल 5<sup>th</sup> / 3<sup>rd</sup> Floor,  
वाई.एम.सी.ए. सांस्कृतिक केन्द्र बिल्डिंग  
YMCA Cultural Center Building,  
1, जय सिंह रोड, नई दिल्ली-110001  
1, Jai Singh Road, N. Delhi – 110001.  
दिनांक :- 28.4.2016

OFFICE MEMORANDUM

**Subject: NLEM, 2015 formulations under provisions of DPCO, 2013.**

With reference to the above, all the concerned manufacturers / marketing companies are requested to furnish the Price to Retailer (PTR) and Moving Annual Turnover (MAT) in value terms for the following formulations for the month of August, 2015, by 10<sup>th</sup> May, 2016, for enabling NPPA to take appropriate action for ceiling price fixation under provisions of DPCO, 2013.

2. The abovementioned information may be furnished within the stipulated period so that NPPA is able to fix the ceiling prices without resorting to exercise of its powers under exceptional provisions under DPCO, 2013 in public interest.

Sl. No.	Section of NLEM No.	Sub-Section of NLEM	Medicines	Dosage form and Strength
1.	1	1.3.3	Midazolam	Oral liquid 2 mg/ml
2.	3	3.3	Chlorpheniramine	Oral liquid 2 mg/5 ml
3.	5	5.3	Diazepam	Oral liquid 2 mg/5 ml
4.	5	5.8	Phenytoin	Oral liquid 30 mg/5 ml
5.	5	5.8	Phenytoin	Oral liquid 125 mg/5 ml
6.	6	6.2.2.5	Doxycycline	Dry Syrup 50mg/5 ml
7.	6	6.2.4.10	Para-aminosalicylic acid	Granules (As licensed)
8.	6	6.2.4.11	Pyrazinamide	Oral liquid 250 mg/5 ml
9.	6	6.3.3	Fluconazole	Oral liquid 50 mg/5 m
10.	6	6.3.5	Nystatin	Oral Liquid 100, 000 IU/ml
11.	6	6.4.3.1.8	Zidovudine	Oral liquid 50 mg/5 ml
12.	6	6.4.3.4.3	Lopinavir (A) + Ritonavir (B)	Oral liquid 400 mg (A) + 100 mg (B)/ 5ml
13.	6	6.2.1.5	Benzyl penicillin	Powder for Injection 10 lac units

14.	6	6.4.4.2	Pegylated interferon alfa 2b	Injection 120 mcg
15.	6	6.5.3.1.1	Artemether (A) + Lumefantrine (B)	Oral liquid 80 mg (A) + 480 mg (B)/5 ml
16.	8	8.4.15	Zoledronic acid	Powder for Injection 4 mg
17.	8	8.1.5	Arsenic trioxide	Injection 1mg/ml
18.	10	10.1.3	Ferrous salt (A) + Folic acid (B)	Oral liquid 20 mg elemental iron (A) + 100 mcg (B)/ml
19.	11	11.1.3	Red blood cells	As licensed
20.	11	11.1.4	Whole blood	As licensed
21.	14	14.2.3	Methylrosanilinium chloride (Gentian Violet)	Topical preparation 0.25% to 2%
22.	14	14.3.1	Betamethasone	Cream 0.1%
23.	14	14.4.3	Podophyllin resin	Solution 10% to 25%
24.	14	14.6.2	White Petrolatum	Jelly 100%
25.	15	15.2.2	Gadobenate	Injection 529 mg/ml
26.	16	16.1	Haemodialysis fluid	As licensed
27.	18	18.1	Furosemide	Oral liquid 10 mg/ml
28.	19	19.1	Budesonide	Nasal Spray 50 mcg/dose
29.	19	19.1	Budesonide	Nasal Spray 100 mcg/dose
30.	20	20.4.1	Dicyclomine	Oral Solution 10mg/5ml
31.	20	20.1.1	Omeprazole	Powder for oral liquid 20 mg
32.	21	21.1.3	Hydrocortisone	Injection 100mg/ml
33.	22	22.2.6	Human normal immunoglobulin	
34.	22	22.3.1.2	DPT + Hib + Hep B vaccine	
35.	22	22.3.1.5	Japanese encephalitis vaccine	
36.	24	24.3	Surfactant	Suspension for intratracheal instillation (As licensed)
37.	25	25.2.1	Prednisolone	Drops 0.1%
38.	25	25.5.3	Phenylephrine	Drops 10 %
39.	25	25.1.3	Erythromycin	Ointment 0.5%
40.	30	30.9	Vitamin A	Oral liquid 100000 IU/ml

*AK*  
(ए. के. खुराना)  
निदेशक

Copy to:

Apex Pharma Associations i.e. OPPI, IDMA, AISSPMA, FICCI, CII, IPA and FOPE for information & necessary action please.